Proteinuria Reduction
-
Telitacicept Shows Promise in IgA Nephropathy Phase 3 Trial in China
Vor Bio (VOR) announced positive Phase 3 results for telitacicept in IgA nephropathy (IgAN) patients in China. The study met its primary endpoint, demonstrating a statistically significant 58.9% reduction in proteinuria versus 8.8% for placebo at Week 39 (p<.0001). Telitacicept also showed stabilization of kidney function and a reduced risk of eGFR decline. Serious adverse events were less frequent with telitacicept. RemeGen has submitted a BLA to China’s CDE for telitacicept in IgAN.
